JPS637526B2 - - Google Patents
Info
- Publication number
- JPS637526B2 JPS637526B2 JP57020614A JP2061482A JPS637526B2 JP S637526 B2 JPS637526 B2 JP S637526B2 JP 57020614 A JP57020614 A JP 57020614A JP 2061482 A JP2061482 A JP 2061482A JP S637526 B2 JPS637526 B2 JP S637526B2
- Authority
- JP
- Japan
- Prior art keywords
- ahedp
- administration
- bone
- concentration
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000000988 bone and bone Anatomy 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 150000004697 chelate complex Chemical class 0.000 claims description 2
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 claims description 2
- 230000006371 metabolic abnormality Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 description 23
- 238000012360 testing method Methods 0.000 description 14
- 230000037396 body weight Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 12
- 239000011575 calcium Substances 0.000 description 12
- 229910052791 calcium Inorganic materials 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 229910052698 phosphorus Inorganic materials 0.000 description 10
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000011574 phosphorus Substances 0.000 description 9
- 230000006872 improvement Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 229910000389 calcium phosphate Inorganic materials 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 235000021317 phosphate Nutrition 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- XGYCHIPEPHYUIH-UHFFFAOYSA-N 2-mdp Chemical compound C=1C=CC=CC=1C(O)(C(CN)C)C1=CC=CC=C1 XGYCHIPEPHYUIH-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000001506 calcium phosphate Substances 0.000 description 6
- 235000011010 calcium phosphates Nutrition 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 208000030159 metabolic disease Diseases 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 208000006386 Bone Resorption Diseases 0.000 description 5
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 5
- 230000024279 bone resorption Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229960002591 hydroxyproline Drugs 0.000 description 5
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 230000036325 urinary excretion Effects 0.000 description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000003076 Osteolysis Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000003625 skull Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000018083 Bone metabolism disease Diseases 0.000 description 2
- 208000004434 Calcinosis Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229910052586 apatite Inorganic materials 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 230000033558 biomineral tissue development Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- -1 etc.) Polymers 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000002988 nephrogenic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000000381 Familial Hypophosphatemia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 229910004856 PâOâP Inorganic materials 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000035563 calcemia Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 230000035564 calciuria Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- XHRPOTDGOASDJS-UHFFFAOYSA-N cholesterol n-octadecanoate Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCCCC)C2 XHRPOTDGOASDJS-UHFFFAOYSA-N 0.000 description 1
- XHRPOTDGOASDJS-XNTGVSEISA-N cholesteryl stearate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1 XHRPOTDGOASDJS-XNTGVSEISA-N 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical compound OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000009519 pharmacological trial Methods 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more PâC bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
æ¬çºæã¯éªšä»£è¬ç°åžžæ²»çå€ã«é¢ãããããã«è©³
ããã¯ãæ¬çºæã¯åŒïŒïŒïŒ ã§è¡šããããïŒâã¢ããâïŒâããããã·ãããµ
ã³âïŒïŒïŒâãžãã¹ãã³é žïŒä»¥äžãAHEDPãšã
ãïŒããã®é žä»å å¡©ããã®ãšã¹ãã«åç©ãŸãã¯ã
ããšé ãšã®ãã¬ãŒãé¯ååç©ãæå¹æåãšãã骚
代è¬ç°åžžæ²»çå€ã«é¢ããã åçž®ãããã¹ããšãŒãïŒphosphatesïŒãäœæ¿
床ã§ååšãããããšã«ããã溶液äžã§ã®çé žã«ã«
ã·ãŠã ã®å ç©ãé¿ããããšãã§ãããšããããšã¯
ç¥ãããŠããããã®äœçšã«å ããŠãåçž®ãããã¹
ããšãŒãïŒãªããã¥ããããã¹ããšãŒãïŒã¯ãã
ãšããããããäœæ¿åºŠã§ãªã³é žã«ã«ã·ãŠã 溶液ã«
å ãããããšããŠããªã³é žã«ã«ã·ãŠã ã®æ²æŸ±ãæ
å¶ãããšããäœçšãæããããã®æå¶æŽ»æ§ã¯çç°
ç³ã®çµæ¶ãå«æããŠããªã溶液ã§ãããŸãåãã€
ãŠçæããçµæ¶ãå«æããŠãã溶液ã«ãããŠãèª
ããããã ããã«åçž®ãããã¹ããšãŒãã¯ããªã³é žã«ã«ã·
ãŠã ãéæ¶è³ªå±€ããæ¶è³ªå±€ã«å€æãããšãã®é床
ããéæ¶è³ªå±€çæã«åœ±é¿ãäžããããšãªãã«ãé
ããããšããäœçšãæããããããã¹ããšãŒã
ïŒä»¥äžãPPãšããïŒãè©Šéšç®¡å è©ŠéšïŒinvitroïŒã«
ãããŠãäœæ¶²æ¿åºŠã«è¿ããªã³é žã«ã«ã·ãŠã ã«å¯Ÿã
ãŠç€ºããã®äœçšã¯ãPPãé±åäœçš
ïŒmineralizationïŒããè»çµç¹ïŒsoft tissueïŒã
ä¿è·ããŠãããšããããšã瀺åããŠããããŸã骚
ã«ãããŠã¯ãPPã¯ã«ã«ã·ãŠã æ²çã®çé·
ïŒdevelopmentïŒã調ç¯ããããããã«ã«ã·ãŠã
ãšãªã³é žå¡©ã®å€æã«åœ±é¿ãäžããããã§ã«é±åã
ã骚ã«ãããPPã®ããïŒã€ã®äœçšã¯ãã«ã«ã·ãŠ
ã ããã³ãã¹ããšãŒãã®éªšã®å å€éšã«ãããéå
床ïŒdegree of movementïŒãžã®åœ±é¿ã§ãããšè
ãããããPPã¯ãã®ãããªè¬çäœçšãæããã«
ããããããããããçµå£æäžãŸãã¯éçµå£
ïŒsystemic routeïŒæäžãããšãã°ããå æ°Žå解
ãããŠããŸãããã«ããããå»è¬ãšããŠçšããã
ãšã¯è¡ãªãããŠããªããåäžã®çç±ããã³PPã«
察ããèå³ãããPPãšåæ§ã®è¬çå¹æãæãã
ã€å æ°Žå解ãããªãç©è³ªãæäŸããè©Šã¿ãçš®ã ãª
ãããŠããŠããããã®ç®çã¯ïŒ°ââçµåãæ
ããååç©ã®ä»£ããã«ïŒ°ââçµåãæããå
åç©ãçšããããšã§å°ãªããšããã®äžéšãéæã
ããŠããããžãã¹ãããŒãïŒdiphosphonateïŒã®
ã«ã«ã·ãŠã å¡©ã«å¯Ÿããäœçšã¯äœæ¿åºŠã«ãããŠã
PPã«ããäœçšãšäŒŒãŠãããäºå®ãã€ãã®(a)ã(d)
ã®äœçšãèªããããã (a) 溶液ãããªã³é žã«ã«ã·ãŠã ãæ²æŸ±ããã®ãæ
å¶ããã (b) ãªã³é žã«ã«ã·ãŠã ã®éæ¶è³ªå±€ããæ¶è³ªå±€ãžã®
å€æãéæ¶è³ªå±€çæãæå¶ããããšãªãã«é»æ¢
ããã (c) ããããã·âçç°ç³ïŒhydroxyâapatiteïŒ
ã®åçž®ãé»æ¢ããã (d) çç°ç³ããžãã¹ãããŒãã溶液ããåžåãã
ã®ã¡ãããããã·âçç°ç³ã®çµæ¶ã®æº¶è§£ã®åºŠå
ãäœããã ç§åŠæç®ã«ãããŠè¿°ã¹ãããŠããå€ãã®è¬çåŠ
çç 究ããã³èšåºåŠçç 究ã«ããã°ãä»æ¥ãŸã§ã«
骚代è¬ç°åžžã®æ²»çã«çšããããŠããŠããçš®ã ã®ãž
ãã¹ãããŒãé¡ã¯PPãšåæ§ã®æŽ»æ§ãæããŠãã
ã«ãããããããããã€ãã®æ¬ ç¹ããæããŠã
ããããªãã¡ããã®æ¬ ç¹ãšã¯åç©ã«å¯ŸããŠçšãã
éã®ç¡èŠãããªãæ¯æ§ããã³ããã«å¯ŸããŠçšãã
éã®èæ§ãŸãã¯å¯äœçšã®èªçºã®åé¡ã§ããã æ¬çºæè ã¯ãããæ¬ ç¹ãå æãã¹ãéæç 究ã
éããçµæãåèšåŒïŒïŒã§è¡šãããã
AHEDPããã®é žä»å å¡©ããã®ãšã¹ãã«åç©ãŸã
ã¯ãããšé ãšã®ãã¬ãŒãé¯ååç©ãçš®ã ã®éªšä»£è¬
ç°åžžã®æ²»çã«éåžžã«æå¹ã§ããããããåŸæ¥ã®éªš
代è¬ç°åžžæ²»çå€ã«ãããŠã¿ãããå¯äœçšãæããŠ
ããªããã®ã§ãããšããé©ãã¹ãäºå®ãèŠåºãã
æ¬çºæãå®æããã«ããã€ãã AHEDPã¯ãããšãã°ã€ãã®è£œé äŸã«ç€ºãæ¹æ³
ã«ãã€ãŠè£œé ãããã 補é äŸ ïŒâã¢ãããããµã³é žããªã«ããªã³é žããã³äž
å¡©åãªã³ãã¢ã«æ¯ã§ïŒïŒïŒïŒïŒã§çšããã¯ããã
ã³ãŒã³äžã«å ããæ··åç©ã80ã90âã§ïŒãïŒæé
å ç±ãããåå¿çµäºåŸãåå¿æ¶²ãå·åŽããã€ãã§
æ°·æ°Žã«æ³šãå ãããã¯ãããã³ãŒã³ãé©åœãªã¬ã¹
æ°æµã§é€å»ããã®ã¡ãçæç©ãå·åŽããã€ãã§æž
å§éãããããããŠããããåºåœ¢ç©ã¯ãçšæ°Žé ž
åãããªãŠã 溶液ã«æº¶è§£ããããã€ãã§å¡©é žãå
ããŠPHãçŽ4.5ã«èª¿ç¯ããåæ²æŸ±ãããæ¹æ³ã«ã
ã€ãŠç²Ÿè£œããã çæç©ïŒAHEDPïŒã¯çœè²ç²ç¶çµæ¶ã§ãããåœ
ã¢ã«ã®çµæ¶æ°Žãå«æãããã®ã§ãã€ãããŸããã®
èç¹ã¯ã枬å®ãããšãã®å ç±é床ã«ãã€ãŠç°ãª
ãã130ãçŽ230âã®éã§ãã€ãã該çµæ¶ã¯æ°Žã«ã
ããã«å¯æº¶ã§ãããåœéã®æ°Žé žåãããªãŠã ãå
ããããšã«ãã€ãŠå®å šã«æº¶è§£ããããŸãéåžžæ¿åºŠ
ã®å¡©é žã«å¯æº¶ã§ãã€ããå çŽ åæã®å®æž¬å€ã¯ãç
æç©ã®åååŒãC6H17NO7P2ã»H2OãšããŠç®åºã
ãçè«å€ã«ã»ãŒäžèŽãããKBré å€æ³ã«ãã€ãŠ
枬å®ããIRã¹ãã¯ãã«åæå€ã¯ã€ãã®ãšããã§
ãã€ãã 3700ã2400cm-1ïŒé žã®OHãã¢ã«ã³ãŒã«åºã®OH
ããã³NHåºã®äŒžçž®æ¯åã®éãªã€ãåžå垯ïŒã
3000ã2700cm-1ïŒCH2ã®äŒžçž®æ¯åïŒã1635ã1520cm
-1ïŒéšåçã«ãã¹ãã³é žãšå¡©ã圢æããŠããã¢ã
ãåºã®å€è§æ¯åïŒã1470cm-1ïŒCH2ã®å€è§æ¯åïŒã
1200cm-1ïŒäŒåããïŒïŒ¯ã®äŒžçž®æ¯åïŒã1150cm-1
ïŒã¢ã«ã³ãŒã«åºã®ïŒ£âã®äŒžçž®æ¯åïŒã1100ã900
cm-1ïŒäŒåããâã®äŒžçž®æ¯åïŒã850ã750cm-1
ïŒæ§é çã«ç°ãªãCH2ã®æšªããæ¯åïŒã600ã400cm
-1ïŒãªã³ååãå«æããççŽ éã®éšåã«ããéªšæ Œ
ã®åžåïŒ ãŸãçæç©ãNaOHã§äžåããéæ°ŽïŒD2OïŒäž
ã§æž¬å®ããNMRã¹ãã¯ãã«åæå€ã¯ã€ãã®ãšã
ãã§ãã€ãã 1.2ã2.4ïŒïœã8HãïŒåã®CH2ïŒã 2.8ã3.1ïŒïœã2HãCH2âNH2ïŒã 3.8ã5.1ïŒæ°ŽãOHãNH2ã«ãããããŒããª
åžåïŒppm ã€ãã«AHEDPã®è¬çâèšåºåŠçæ§è³ªããã³æ¯
æ§ã«ã€ããŠè¿°ã¹ããè¬çè©Šéšã¯ãé 骚ïŒskullïŒ
ã®çŽ°èã«å¯Ÿããäœçšã«ã€ããŠã¯å¹é€æ³
ïŒincultureïŒã«ãã€ãŠèª¿ã¹ãäœéªšïŒboneïŒã®ååž
åããã³é±åäœçšã«ã€ããŠã¯çäœå è©ŠéšïŒin
vivoïŒã«ãã€ãŠèª¿ã¹ãæ¯æ§ã«ã€ããŠã¯ããŠã¹ãçš
ããŠèª¿ã¹ãã è¬çè©Šéš ïŒ ïŒé èå 现èã«å¯Ÿãã掻æ§è©ŠéšïŒ 现èå¹é€ïŒé èå 现èããŸããã¢ãŒã¹ã
ïŒFastïŒãã®æ¹æ³ïŒBiochemical Journalã172ã
97ã107ïŒ1978ïŒåç §ïŒã«ãããã€ãŠå¹é€ãããã
ãªãã¡ãçåŸïŒæ¥ã®ãŠã€ã¹ã¿ãŒã»ã©ããããæåº
ããé 骚ãã³ã©ãŒã²ããŒãŒã§æ¶åïŒdigestïŒãã
ããéé¢çŽ°èïŒfreed cellsïŒã¯ã1.5mlã®å¹é€æ¶²
ãæããçŽåŸ3.5cmã®ãããªç¿ããã³0.5mlã®å¹é€
液ãæããçŽåŸ1.6cmã®ç¿ãžå ããŠå¹é€æ¶²ïŒmlã
ãã20000åã®çŽ°èæ¿åºŠãšããããã®çŽ°èã¯å°ãª
ããšãèå ã®åçã®è¡æž ã®10ïŒ ãå«æããå¹å°ã§
ïŒïŒ CO2é°å²æ°äžã37âã§ïŒãïŒæ¥éå¹é€ããã
ãžãã¹ãããŒãé¡ã¯è©Šéšéå§ããçµäºãŸã§æ·»å ã
ãã 现èã¯ãã³ã©ãŒã²ããŒãŒããã³ããªãã·ã³ã®æ··
åç©ã«ããæ¶åã«ãã€ãŠå¹é€ç¿ããéé¢ãããã®
ã¡ããã®æ°ãã¯ãŒã«ã¿ãŒã«ãŠã³ã¿ãŒïŒCoulter
counterïŒã§èšæž¬ãããïŒæ¥ç®ã«ãæ··åç©ãå ¥ã
æãã现èã16æéå¹é€ïŒincubateïŒããããã®
éã«ããããã©ã¯ããŒãïŒLactateïŒã®éããã¢
ãŒã¹ããã®æ¹æ³ã«ãã€ãŠæž¬å®ããã è¬çè©Šéš ïŒ ïŒéªšã®ååžåããã³çäœå è©Šéšã«ãããã«ã«ã·
ãŠã æ²çïŒcalcificationïŒïŒ ãŠã€ã¹ã¿ãŒã»ã©ããïŒäœé180ã200ïœïŒãïŒå¹
ãã€ã®æ°ã°ã«ãŒãã«åããAHEDPããªã³ã«æç®
ããŠãããã0.01mgïŒKgäœéã0.1mgïŒKgäœéã
1.0mgïŒKgäœéãããã¯10mgïŒKgäœéãŸãã¯çç
溶液ãïŒæ¥éç®äžæ³šå°ã«ãã€ãŠæ¯æ¥æäžãããã
ããã®å®éšåç©ã«ã¯100ïœãããã«ã«ã·ãŠã 1.1
ïœããªã³1.2ïœããã³ãã¿ãã³D3ã®250IUãå«æ
ããã¢ã«ãããã€ã³1314ïŒAltromine1314ïŒãé€
ãšããŠãããããïŒæ¥ç®ã«å®éšåç©ãèŽæ»ããã
è骚ïŒtibia boneïŒãæåºãã50ïŒ ãšã¿ããŒã«äž
ã«ä¿åãããããã®è骚ã¯ã€ãã«çµç¹åŠçæ€æ»ã®
ããã«ãåã70ã80ÎŒã®æçãšããŠãã€ã¯ãã©ãž
ãªã°ã©ãã€ãŒçè©Šéšã«äŸããããã®æ¹æ³ã«ãã骚
幹端ã®é±ç©æ¿åºŠãèŠç©ãããšãå¯èœãšãªã
ïŒSchenkïŒet alïŒCalc.Tiss.Res.ã11ã196ã214
ïŒ1973ïŒåç §ïŒã ïŒè©ŠéšçµæïŒ è©Šéšã«çšããæ¿åºŠã«ãããŠãè¬çè©ŠéšïŒã§ã¯
250ÎŒMã®æ¿åºŠã®ã°ããã ããããããã®å¹æã
æããããšã瀺ããããšããã®ã¯ãããã¯çŽ°èã®
æ°ã«ãããŠã¯ããåãã®æžå°ã瀺ãããã®ã®ãã©
ã¯ããŒãçæã«ãããŠã¯å¢å ããŠããããã§ã
ãããŸãäœæ¿åºŠã«ãããŠã现èã®æåã«ã¯ããã€
ãã¹ã®å¹æã¯èªããããªãã€ããããããçµæã
第ïŒè¡šã«ç€ºãããªã第ïŒè¡šäžãAPDã¯æ¯èŒäŸãš
ããŠçšããïŒâã¢ããâïŒâããããã·ãããã³
âïŒïŒïŒâãžãã¹ãã³é žã瀺ãã
ããã¯ãæ¬çºæã¯åŒïŒïŒïŒ ã§è¡šããããïŒâã¢ããâïŒâããããã·ãããµ
ã³âïŒïŒïŒâãžãã¹ãã³é žïŒä»¥äžãAHEDPãšã
ãïŒããã®é žä»å å¡©ããã®ãšã¹ãã«åç©ãŸãã¯ã
ããšé ãšã®ãã¬ãŒãé¯ååç©ãæå¹æåãšãã骚
代è¬ç°åžžæ²»çå€ã«é¢ããã åçž®ãããã¹ããšãŒãïŒphosphatesïŒãäœæ¿
床ã§ååšãããããšã«ããã溶液äžã§ã®çé žã«ã«
ã·ãŠã ã®å ç©ãé¿ããããšãã§ãããšããããšã¯
ç¥ãããŠããããã®äœçšã«å ããŠãåçž®ãããã¹
ããšãŒãïŒãªããã¥ããããã¹ããšãŒãïŒã¯ãã
ãšããããããäœæ¿åºŠã§ãªã³é žã«ã«ã·ãŠã 溶液ã«
å ãããããšããŠããªã³é žã«ã«ã·ãŠã ã®æ²æŸ±ãæ
å¶ãããšããäœçšãæããããã®æå¶æŽ»æ§ã¯çç°
ç³ã®çµæ¶ãå«æããŠããªã溶液ã§ãããŸãåãã€
ãŠçæããçµæ¶ãå«æããŠãã溶液ã«ãããŠãèª
ããããã ããã«åçž®ãããã¹ããšãŒãã¯ããªã³é žã«ã«ã·
ãŠã ãéæ¶è³ªå±€ããæ¶è³ªå±€ã«å€æãããšãã®é床
ããéæ¶è³ªå±€çæã«åœ±é¿ãäžããããšãªãã«ãé
ããããšããäœçšãæããããããã¹ããšãŒã
ïŒä»¥äžãPPãšããïŒãè©Šéšç®¡å è©ŠéšïŒinvitroïŒã«
ãããŠãäœæ¶²æ¿åºŠã«è¿ããªã³é žã«ã«ã·ãŠã ã«å¯Ÿã
ãŠç€ºããã®äœçšã¯ãPPãé±åäœçš
ïŒmineralizationïŒããè»çµç¹ïŒsoft tissueïŒã
ä¿è·ããŠãããšããããšã瀺åããŠããããŸã骚
ã«ãããŠã¯ãPPã¯ã«ã«ã·ãŠã æ²çã®çé·
ïŒdevelopmentïŒã調ç¯ããããããã«ã«ã·ãŠã
ãšãªã³é žå¡©ã®å€æã«åœ±é¿ãäžããããã§ã«é±åã
ã骚ã«ãããPPã®ããïŒã€ã®äœçšã¯ãã«ã«ã·ãŠ
ã ããã³ãã¹ããšãŒãã®éªšã®å å€éšã«ãããéå
床ïŒdegree of movementïŒãžã®åœ±é¿ã§ãããšè
ãããããPPã¯ãã®ãããªè¬çäœçšãæããã«
ããããããããããçµå£æäžãŸãã¯éçµå£
ïŒsystemic routeïŒæäžãããšãã°ããå æ°Žå解
ãããŠããŸãããã«ããããå»è¬ãšããŠçšããã
ãšã¯è¡ãªãããŠããªããåäžã®çç±ããã³PPã«
察ããèå³ãããPPãšåæ§ã®è¬çå¹æãæãã
ã€å æ°Žå解ãããªãç©è³ªãæäŸããè©Šã¿ãçš®ã ãª
ãããŠããŠããããã®ç®çã¯ïŒ°ââçµåãæ
ããååç©ã®ä»£ããã«ïŒ°ââçµåãæããå
åç©ãçšããããšã§å°ãªããšããã®äžéšãéæã
ããŠããããžãã¹ãããŒãïŒdiphosphonateïŒã®
ã«ã«ã·ãŠã å¡©ã«å¯Ÿããäœçšã¯äœæ¿åºŠã«ãããŠã
PPã«ããäœçšãšäŒŒãŠãããäºå®ãã€ãã®(a)ã(d)
ã®äœçšãèªããããã (a) 溶液ãããªã³é žã«ã«ã·ãŠã ãæ²æŸ±ããã®ãæ
å¶ããã (b) ãªã³é žã«ã«ã·ãŠã ã®éæ¶è³ªå±€ããæ¶è³ªå±€ãžã®
å€æãéæ¶è³ªå±€çæãæå¶ããããšãªãã«é»æ¢
ããã (c) ããããã·âçç°ç³ïŒhydroxyâapatiteïŒ
ã®åçž®ãé»æ¢ããã (d) çç°ç³ããžãã¹ãããŒãã溶液ããåžåãã
ã®ã¡ãããããã·âçç°ç³ã®çµæ¶ã®æº¶è§£ã®åºŠå
ãäœããã ç§åŠæç®ã«ãããŠè¿°ã¹ãããŠããå€ãã®è¬çåŠ
çç 究ããã³èšåºåŠçç 究ã«ããã°ãä»æ¥ãŸã§ã«
骚代è¬ç°åžžã®æ²»çã«çšããããŠããŠããçš®ã ã®ãž
ãã¹ãããŒãé¡ã¯PPãšåæ§ã®æŽ»æ§ãæããŠãã
ã«ãããããããããã€ãã®æ¬ ç¹ããæããŠã
ããããªãã¡ããã®æ¬ ç¹ãšã¯åç©ã«å¯ŸããŠçšãã
éã®ç¡èŠãããªãæ¯æ§ããã³ããã«å¯ŸããŠçšãã
éã®èæ§ãŸãã¯å¯äœçšã®èªçºã®åé¡ã§ããã æ¬çºæè ã¯ãããæ¬ ç¹ãå æãã¹ãéæç 究ã
éããçµæãåèšåŒïŒïŒã§è¡šãããã
AHEDPããã®é žä»å å¡©ããã®ãšã¹ãã«åç©ãŸã
ã¯ãããšé ãšã®ãã¬ãŒãé¯ååç©ãçš®ã ã®éªšä»£è¬
ç°åžžã®æ²»çã«éåžžã«æå¹ã§ããããããåŸæ¥ã®éªš
代è¬ç°åžžæ²»çå€ã«ãããŠã¿ãããå¯äœçšãæããŠ
ããªããã®ã§ãããšããé©ãã¹ãäºå®ãèŠåºãã
æ¬çºæãå®æããã«ããã€ãã AHEDPã¯ãããšãã°ã€ãã®è£œé äŸã«ç€ºãæ¹æ³
ã«ãã€ãŠè£œé ãããã 補é äŸ ïŒâã¢ãããããµã³é žããªã«ããªã³é žããã³äž
å¡©åãªã³ãã¢ã«æ¯ã§ïŒïŒïŒïŒïŒã§çšããã¯ããã
ã³ãŒã³äžã«å ããæ··åç©ã80ã90âã§ïŒãïŒæé
å ç±ãããåå¿çµäºåŸãåå¿æ¶²ãå·åŽããã€ãã§
æ°·æ°Žã«æ³šãå ãããã¯ãããã³ãŒã³ãé©åœãªã¬ã¹
æ°æµã§é€å»ããã®ã¡ãçæç©ãå·åŽããã€ãã§æž
å§éãããããããŠããããåºåœ¢ç©ã¯ãçšæ°Žé ž
åãããªãŠã 溶液ã«æº¶è§£ããããã€ãã§å¡©é žãå
ããŠPHãçŽ4.5ã«èª¿ç¯ããåæ²æŸ±ãããæ¹æ³ã«ã
ã€ãŠç²Ÿè£œããã çæç©ïŒAHEDPïŒã¯çœè²ç²ç¶çµæ¶ã§ãããåœ
ã¢ã«ã®çµæ¶æ°Žãå«æãããã®ã§ãã€ãããŸããã®
èç¹ã¯ã枬å®ãããšãã®å ç±é床ã«ãã€ãŠç°ãª
ãã130ãçŽ230âã®éã§ãã€ãã該çµæ¶ã¯æ°Žã«ã
ããã«å¯æº¶ã§ãããåœéã®æ°Žé žåãããªãŠã ãå
ããããšã«ãã€ãŠå®å šã«æº¶è§£ããããŸãéåžžæ¿åºŠ
ã®å¡©é žã«å¯æº¶ã§ãã€ããå çŽ åæã®å®æž¬å€ã¯ãç
æç©ã®åååŒãC6H17NO7P2ã»H2OãšããŠç®åºã
ãçè«å€ã«ã»ãŒäžèŽãããKBré å€æ³ã«ãã€ãŠ
枬å®ããIRã¹ãã¯ãã«åæå€ã¯ã€ãã®ãšããã§
ãã€ãã 3700ã2400cm-1ïŒé žã®OHãã¢ã«ã³ãŒã«åºã®OH
ããã³NHåºã®äŒžçž®æ¯åã®éãªã€ãåžå垯ïŒã
3000ã2700cm-1ïŒCH2ã®äŒžçž®æ¯åïŒã1635ã1520cm
-1ïŒéšåçã«ãã¹ãã³é žãšå¡©ã圢æããŠããã¢ã
ãåºã®å€è§æ¯åïŒã1470cm-1ïŒCH2ã®å€è§æ¯åïŒã
1200cm-1ïŒäŒåããïŒïŒ¯ã®äŒžçž®æ¯åïŒã1150cm-1
ïŒã¢ã«ã³ãŒã«åºã®ïŒ£âã®äŒžçž®æ¯åïŒã1100ã900
cm-1ïŒäŒåããâã®äŒžçž®æ¯åïŒã850ã750cm-1
ïŒæ§é çã«ç°ãªãCH2ã®æšªããæ¯åïŒã600ã400cm
-1ïŒãªã³ååãå«æããççŽ éã®éšåã«ããéªšæ Œ
ã®åžåïŒ ãŸãçæç©ãNaOHã§äžåããéæ°ŽïŒD2OïŒäž
ã§æž¬å®ããNMRã¹ãã¯ãã«åæå€ã¯ã€ãã®ãšã
ãã§ãã€ãã 1.2ã2.4ïŒïœã8HãïŒåã®CH2ïŒã 2.8ã3.1ïŒïœã2HãCH2âNH2ïŒã 3.8ã5.1ïŒæ°ŽãOHãNH2ã«ãããããŒããª
åžåïŒppm ã€ãã«AHEDPã®è¬çâèšåºåŠçæ§è³ªããã³æ¯
æ§ã«ã€ããŠè¿°ã¹ããè¬çè©Šéšã¯ãé 骚ïŒskullïŒ
ã®çŽ°èã«å¯Ÿããäœçšã«ã€ããŠã¯å¹é€æ³
ïŒincultureïŒã«ãã€ãŠèª¿ã¹ãäœéªšïŒboneïŒã®ååž
åããã³é±åäœçšã«ã€ããŠã¯çäœå è©ŠéšïŒin
vivoïŒã«ãã€ãŠèª¿ã¹ãæ¯æ§ã«ã€ããŠã¯ããŠã¹ãçš
ããŠèª¿ã¹ãã è¬çè©Šéš ïŒ ïŒé èå 现èã«å¯Ÿãã掻æ§è©ŠéšïŒ 现èå¹é€ïŒé èå 现èããŸããã¢ãŒã¹ã
ïŒFastïŒãã®æ¹æ³ïŒBiochemical Journalã172ã
97ã107ïŒ1978ïŒåç §ïŒã«ãããã€ãŠå¹é€ãããã
ãªãã¡ãçåŸïŒæ¥ã®ãŠã€ã¹ã¿ãŒã»ã©ããããæåº
ããé 骚ãã³ã©ãŒã²ããŒãŒã§æ¶åïŒdigestïŒãã
ããéé¢çŽ°èïŒfreed cellsïŒã¯ã1.5mlã®å¹é€æ¶²
ãæããçŽåŸ3.5cmã®ãããªç¿ããã³0.5mlã®å¹é€
液ãæããçŽåŸ1.6cmã®ç¿ãžå ããŠå¹é€æ¶²ïŒmlã
ãã20000åã®çŽ°èæ¿åºŠãšããããã®çŽ°èã¯å°ãª
ããšãèå ã®åçã®è¡æž ã®10ïŒ ãå«æããå¹å°ã§
ïŒïŒ CO2é°å²æ°äžã37âã§ïŒãïŒæ¥éå¹é€ããã
ãžãã¹ãããŒãé¡ã¯è©Šéšéå§ããçµäºãŸã§æ·»å ã
ãã 现èã¯ãã³ã©ãŒã²ããŒãŒããã³ããªãã·ã³ã®æ··
åç©ã«ããæ¶åã«ãã€ãŠå¹é€ç¿ããéé¢ãããã®
ã¡ããã®æ°ãã¯ãŒã«ã¿ãŒã«ãŠã³ã¿ãŒïŒCoulter
counterïŒã§èšæž¬ãããïŒæ¥ç®ã«ãæ··åç©ãå ¥ã
æãã现èã16æéå¹é€ïŒincubateïŒããããã®
éã«ããããã©ã¯ããŒãïŒLactateïŒã®éããã¢
ãŒã¹ããã®æ¹æ³ã«ãã€ãŠæž¬å®ããã è¬çè©Šéš ïŒ ïŒéªšã®ååžåããã³çäœå è©Šéšã«ãããã«ã«ã·
ãŠã æ²çïŒcalcificationïŒïŒ ãŠã€ã¹ã¿ãŒã»ã©ããïŒäœé180ã200ïœïŒãïŒå¹
ãã€ã®æ°ã°ã«ãŒãã«åããAHEDPããªã³ã«æç®
ããŠãããã0.01mgïŒKgäœéã0.1mgïŒKgäœéã
1.0mgïŒKgäœéãããã¯10mgïŒKgäœéãŸãã¯çç
溶液ãïŒæ¥éç®äžæ³šå°ã«ãã€ãŠæ¯æ¥æäžãããã
ããã®å®éšåç©ã«ã¯100ïœãããã«ã«ã·ãŠã 1.1
ïœããªã³1.2ïœããã³ãã¿ãã³D3ã®250IUãå«æ
ããã¢ã«ãããã€ã³1314ïŒAltromine1314ïŒãé€
ãšããŠãããããïŒæ¥ç®ã«å®éšåç©ãèŽæ»ããã
è骚ïŒtibia boneïŒãæåºãã50ïŒ ãšã¿ããŒã«äž
ã«ä¿åãããããã®è骚ã¯ã€ãã«çµç¹åŠçæ€æ»ã®
ããã«ãåã70ã80ÎŒã®æçãšããŠãã€ã¯ãã©ãž
ãªã°ã©ãã€ãŒçè©Šéšã«äŸããããã®æ¹æ³ã«ãã骚
幹端ã®é±ç©æ¿åºŠãèŠç©ãããšãå¯èœãšãªã
ïŒSchenkïŒet alïŒCalc.Tiss.Res.ã11ã196ã214
ïŒ1973ïŒåç §ïŒã ïŒè©ŠéšçµæïŒ è©Šéšã«çšããæ¿åºŠã«ãããŠãè¬çè©ŠéšïŒã§ã¯
250ÎŒMã®æ¿åºŠã®ã°ããã ããããããã®å¹æã
æããããšã瀺ããããšããã®ã¯ãããã¯çŽ°èã®
æ°ã«ãããŠã¯ããåãã®æžå°ã瀺ãããã®ã®ãã©
ã¯ããŒãçæã«ãããŠã¯å¢å ããŠããããã§ã
ãããŸãäœæ¿åºŠã«ãããŠã现èã®æåã«ã¯ããã€
ãã¹ã®å¹æã¯èªããããªãã€ããããããçµæã
第ïŒè¡šã«ç€ºãããªã第ïŒè¡šäžãAPDã¯æ¯èŒäŸãš
ããŠçšããïŒâã¢ããâïŒâããããã·ãããã³
âïŒïŒïŒâãžãã¹ãã³é žã瀺ãã
ãè¡šã
骚ã®ååžåããã³ã«ã«ã·ãŠã æ²çã«å¯Ÿããè©Šéš
ã§ã¯ããªã³æç®æäžéã0.01mgïŒKgäœéã®ã°ã
ãã骚ã®å¯åºŠã«åœ±é¿ã¯èªããããªãã€ããã0.1
mgïŒKgäœéã®ã°ããããšãã«ïŒmgïŒKgäœéã®ã°ã
ãã«ã¯éªšå¹¹ç«¯å¯åºŠã®å¢å ãèªãããã骚ã®ååžå
ãæããã«æå¶ãããŠããã®ãèªããããããŸã
ãªã³æç®æäžé10mgïŒKgäœéã®ã°ãããé€ãã»ã
ã¯ãå®éšåç©ã®äœéã«å€åã¯ãªãã10mgïŒKgäœé
ã®ã°ããã§ãæããã«åé¡ãšãªãäœéå€åã§ã¯ãª
ãã€ãã ããããå®éšçµæã¯ãAHEDPã骚ã®ååžåã®
匷åãªæå¶å€ã§ããããã®æå¶åã¯ããç¥ãããŠ
ãããžãã¹ãããŒãé¡ïŒããšãã°ïŒâã¢ããâïŒ
âããããã·ãããã³âïŒïŒïŒâãžãã¹ãããŒã
ïŒä»¥äžãAPDãšããïŒïŒãšæ¯èŒããŠãåçããŸã
ã¯ããããŠãããšããããšã瀺ããã®ã§ãã€ãã
ãŸãAPDã®ããšãåŸæ¥å ¬ç¥ã®éªšä»£è¬ç°åžžæ²»çå€
ã¯çŽ°èæ¯æ§ããã¡ãããããããïŒAHEDPãšã
ãã¹ããšçŽ100åã®æ¯æ§ïŒããã®ããAHEDPã¯å®
å šæ§ã®éçå€ãéåžžã«ãããããã®ã§ãããšãã
ãã ïŒæ¯æ§è©ŠéšïŒ çäœå è©Šéšã«ããAHEDPã®æ¯æ§è©Šéšã¯ãã¡ã¹
ããã³ãªã¹ã®ã¹ã€ã¹ã»ããŠã¹ãçšããçš®ã ã®æäž
æ¹æ³ã®ã°ããã«ã€ããŠèª¿ã¹ãããŸãæ¯èŒäŸãšããŠ
ã¯ãAPDã®ïŒãããªãŠã å¡©ããšã¿ã³âïŒâãã
ããã·âïŒïŒïŒâãžãã¹ãã³é žïŒä»¥äžãEHDPãš
ããïŒã®ïŒãããªãŠã å¡©ããã³ãžã¯ããã¡ãã¬ã³
ãžãã¹ãã³é žïŒä»¥äžãCl2 MPDãšããïŒã®ïŒã
ããªãŠã å¡©ãçšããã ããããLD50å€ã第ïŒè¡šã«ãŸãšããŠç€ºãã
ã§ã¯ããªã³æç®æäžéã0.01mgïŒKgäœéã®ã°ã
ãã骚ã®å¯åºŠã«åœ±é¿ã¯èªããããªãã€ããã0.1
mgïŒKgäœéã®ã°ããããšãã«ïŒmgïŒKgäœéã®ã°ã
ãã«ã¯éªšå¹¹ç«¯å¯åºŠã®å¢å ãèªãããã骚ã®ååžå
ãæããã«æå¶ãããŠããã®ãèªããããããŸã
ãªã³æç®æäžé10mgïŒKgäœéã®ã°ãããé€ãã»ã
ã¯ãå®éšåç©ã®äœéã«å€åã¯ãªãã10mgïŒKgäœé
ã®ã°ããã§ãæããã«åé¡ãšãªãäœéå€åã§ã¯ãª
ãã€ãã ããããå®éšçµæã¯ãAHEDPã骚ã®ååžåã®
匷åãªæå¶å€ã§ããããã®æå¶åã¯ããç¥ãããŠ
ãããžãã¹ãããŒãé¡ïŒããšãã°ïŒâã¢ããâïŒ
âããããã·ãããã³âïŒïŒïŒâãžãã¹ãããŒã
ïŒä»¥äžãAPDãšããïŒïŒãšæ¯èŒããŠãåçããŸã
ã¯ããããŠãããšããããšã瀺ããã®ã§ãã€ãã
ãŸãAPDã®ããšãåŸæ¥å ¬ç¥ã®éªšä»£è¬ç°åžžæ²»çå€
ã¯çŽ°èæ¯æ§ããã¡ãããããããïŒAHEDPãšã
ãã¹ããšçŽ100åã®æ¯æ§ïŒããã®ããAHEDPã¯å®
å šæ§ã®éçå€ãéåžžã«ãããããã®ã§ãããšãã
ãã ïŒæ¯æ§è©ŠéšïŒ çäœå è©Šéšã«ããAHEDPã®æ¯æ§è©Šéšã¯ãã¡ã¹
ããã³ãªã¹ã®ã¹ã€ã¹ã»ããŠã¹ãçšããçš®ã ã®æäž
æ¹æ³ã®ã°ããã«ã€ããŠèª¿ã¹ãããŸãæ¯èŒäŸãšããŠ
ã¯ãAPDã®ïŒãããªãŠã å¡©ããšã¿ã³âïŒâãã
ããã·âïŒïŒïŒâãžãã¹ãã³é žïŒä»¥äžãEHDPãš
ããïŒã®ïŒãããªãŠã å¡©ããã³ãžã¯ããã¡ãã¬ã³
ãžãã¹ãã³é žïŒä»¥äžãCl2 MPDãšããïŒã®ïŒã
ããªãŠã å¡©ãçšããã ããããLD50å€ã第ïŒè¡šã«ãŸãšããŠç€ºãã
ãè¡šã
ïŒ ã©ãããçšããçµæ
第ïŒè¡šã«ç€ºããçµæããæãããªããã«ã
AHEDPã¯ã©ã®æäžæ¹æ³ã®ã°ããã§ãäœãæ¯æ§ã
瀺ããããšãã«åæååç©ã§ããAPDã«ããã¹
ãŠã¯ããã«ããããèæ§ã瀺ããããšã¯ç¹çã«å€
ããããŸããã®çµæã¯ããã§ã«è©Šéšç®¡å è©Šéšã§äº
枬ããããšã確蚌ãããã®ã§ããã AHEDPãè¬çåŠçã«ãã€æ¯æ§çã«å¥œãŸããã
ã®ã§ããããšã確ãããããã®ã§ãã€ãã«èšåºåŠ
çè©Šéšãè¡ãªã€ãããã®è©Šéšã¯ã骚ã®ååžåé床
ãéããšããçç¶ã®è±é±åäœçšç骚代è¬ç°åžžã«å¯Ÿ
ããæ²»çå€ãšããŠAHEDPãæäžãããªã³ããã³
ã«ã«ã·ãŠã ã®ä»£è¬ã«ãããå¹æã調ã¹ãããšãã
ãªã€ãŠããã ïŒè¢«éšè ïŒ (i) ããŒãžãšããçãšãããã骚ã®ç æ°ã®æ£è ïŒ
52ã68æã®ç·æ§ïŒåããã³å¥³æ§ïŒå (ii) ä¹³ã¬ã³ã«ãã€ãŠè»¢ç§»æ§ã®éªšæº¶è§£çã䜵çºãã
æ£è ïŒ42ã59æã®å¥³æ§ïŒå ïŒæäžéããã³æäžæéïŒ æäžéããã³æäžæéã¯ç¬¬ïŒè¡šã«ç€ºããšãããš
ããããªãæäžã¯ç¹æ»Žæ³ã«ãã€ãŠè¡ãªã€ãã
第ïŒè¡šã«ç€ºããçµæããæãããªããã«ã
AHEDPã¯ã©ã®æäžæ¹æ³ã®ã°ããã§ãäœãæ¯æ§ã
瀺ããããšãã«åæååç©ã§ããAPDã«ããã¹
ãŠã¯ããã«ããããèæ§ã瀺ããããšã¯ç¹çã«å€
ããããŸããã®çµæã¯ããã§ã«è©Šéšç®¡å è©Šéšã§äº
枬ããããšã確蚌ãããã®ã§ããã AHEDPãè¬çåŠçã«ãã€æ¯æ§çã«å¥œãŸããã
ã®ã§ããããšã確ãããããã®ã§ãã€ãã«èšåºåŠ
çè©Šéšãè¡ãªã€ãããã®è©Šéšã¯ã骚ã®ååžåé床
ãéããšããçç¶ã®è±é±åäœçšç骚代è¬ç°åžžã«å¯Ÿ
ããæ²»çå€ãšããŠAHEDPãæäžãããªã³ããã³
ã«ã«ã·ãŠã ã®ä»£è¬ã«ãããå¹æã調ã¹ãããšãã
ãªã€ãŠããã ïŒè¢«éšè ïŒ (i) ããŒãžãšããçãšãããã骚ã®ç æ°ã®æ£è ïŒ
52ã68æã®ç·æ§ïŒåããã³å¥³æ§ïŒå (ii) ä¹³ã¬ã³ã«ãã€ãŠè»¢ç§»æ§ã®éªšæº¶è§£çã䜵çºãã
æ£è ïŒ42ã59æã®å¥³æ§ïŒå ïŒæäžéããã³æäžæéïŒ æäžéããã³æäžæéã¯ç¬¬ïŒè¡šã«ç€ºããšãããš
ããããªãæäžã¯ç¹æ»Žæ³ã«ãã€ãŠè¡ãªã€ãã
ãè¡šã
ïŒä»£è¬ãã©ã¡ãŒã¿ïŒ
AHEDPã®æäžåãæäžæéäžããã³æäžæé
åŸã«ããããªã³ãšã«ã«ã·ãŠã ã®ä»£è¬ãã©ã¡ãŒã¿ã
ãã³èæ§ãã©ã¡ãŒã¿ã«ã€ããŠèª¿ã¹ãã (A) ãªã³ããã³ã«ã«ã·ãŠã ã®ä»£è¬ãã©ã¡ãŒã¿ïŒè¡
äžã«ã«ã·ãŠã æ¿åºŠãè¡äžãªã³é žå¡©æ¿åºŠãè¡äžã¢
ã«ã«ãªãã¹ãã¢ã¿ãŒãŒæ¿åºŠãè¡æŒ¿äžPGE2ãè¡
挿äžå ç«åå¿æ§PTHãå°¿äžã«ã«ã·ãŠã æ¿åºŠã
å°¿äžãªã³é žå¡©æ¿åºŠãå°¿äžããããã·ãããªã³æ¿
床ãç°ç¶è 圢æAMPïŒcyclic nephrogenic
AMPïŒ (B) èæ§ãã©ã¡ãŒã¿ïŒãã¢ã¯ããŒã è¡çèšæž¬è©Š
éšãè¡äžã¿ã³ãã¯æ¿åºŠãè¡ç³æ¿åºŠãè¡äžããçŽ
æ¿åºŠãè¡äžã¯ã¬ã¢ãã³æ¿åºŠãè¡äžãã©ã³ã¹ã¢ã
ããŒãŒæ¿åºŠãå ç«ã°ãããªã³é ïŒè©ŠéšçµæïŒ ãããã®è¢«éšè ã«ãããŠãAHEDPæäžã«ãã€
ãŠèæ§ãã©ã¡ãŒã¿ã«ç®ç«ã€ãå€åãæ¹ããããã
ãšã¯ãªããããèæ§ã瀺ããããŸããšãã«å¯äœçš
ãèªããããªãã€ãããªã³ããã³ã«ã«ã·ãŠã ã®ä»£
è¬ãã©ã¡ãŒã¿ã«é¢ããéãããšãã«å€åã¯èªãã
ããªãã€ããããã«ã¯ãªã³é žå¡©è¡çã¯ãããã®æ
æã«ãããŠãèªããããªãã€ããã«ã«ã·ãŠã è¡ç
ããã³ã«ã«ã·ãŠã å°¿çã«é¢ããŠã¯ãæ°åã®è¢«éšè
ã«ãããŠéåžžã«çæéã§ã¯ãããèªãããããïŒ
æ¥ãããã®æäžéãïŒmgã10mgã20mgããã³40mg
ã®ãããã®ã°ããã«ãããŠãç²ç¶è ºæäœçšã«é¢ã
ããã©ã¡ãŒã¿ïŒè¡æŒ¿äžå ç«åå¿æ§PTHãç°ç¶è
圢æAMPïŒã®å€§ããªå€åã¯èªããããªãã€ãã å šäœçã«ã¯ããããã®ãã©ã¡ãŒã¿ã¯ãããã«å¢
å ããŠããããåé¡ãšãªãã¬ãã«ã«ãŸã§ã¯éããŠ
ããªãã€ãã AHEDPãïŒæ¥ãããïŒmgãŸãã¯10mgæäžãã
ã被éšè ã«ãããŠã¯ãç¡æ©ã«ã«ã·ãŠã ããã³ç¡æ©
ãªã³é žå¡©ã®å°¿ææ³éã¯ãšãã«æ¹åãããŠããªãã€
ãããAHEDPãïŒæ¥ããã20mgãŸãã¯40mgæäž
ããã被éšè ã«ãããŠã¯ããã®ïŒã€ã®ãã©ã¡ãŒã¿
ã«ããªãã®æ¹åãèªããããããã®å¹æã¯ãšãã«
ãªã³é žå¡©å°¿çã®ã°ããã«æçœã«èªããããã ãã¹ãŠè¢«éšè ãæ£ã€ãŠããé«ã¢ã«ã«ãªãã¹ãã¢
ã¿ãŒãŒè¡çããã³éªšèœçŽ°èçã¯ãïŒæ¥ãããã®æ
äžéãïŒã20mgã§ã¯æãããªæ¹åã¯èªããããã
ïŒæ¥ãããã®æåé40mgã®è¢«éšè ã«ãããŠã®ã¿æ
çœã§ãã€æ©æã®æ¹åãèªããããã ïŒããããã·ãããªã³ã®å°¿ææ³ïŒ 骚ã³ã©ãŒã²ã³ã®ç°åäœçšããã»ã¹ã®ææ°ã§ã
ããAHEDPæäžåã«è¢«éšè ã«ãããŠããªãé«ã
å€ã§ãã€ãããããã·ãããªã³ã®å°¿ææ³éã¯ãã
ã¹ãŠã®è¢«éšè ã«ãããŠããªãã®æžå°ãèªããã
ããããªãã¡ãããããã·ãããªã³ã®å°¿äžæ¿åºŠã¯
AHEDPæäžåã«ããã¹ãŠããªãæžå°ããæäžé
ãå€ãã»ã©ãã®å¹æãé«ããã®ã§ãã€ãã ããŒãžãšããçã®ïŒåã®è¢«éšè ã®ã°ããã
AHEDPæäžåã«ãããŠã¯éªšæº¶è§£çã®äœæ¶²ãã¢ã¯
ã¿ãŒã§ããè¡æŒ¿äžPGE2æ¿åºŠãããªãé«ãå€ã瀺
ããŠãããããããAHEDPãïŒæ¥ããã20ã40
mgæäžããããšã«ãã€ãŠãã®å€ã«ããªãã®ãã€æ©
æã®æžå°ãèªããããããªããã®ïŒåã®è¢«éšè ã®
ãã¡ïŒåã¯ãã®åã«ïŒæ¥ãããAHEDPã10mgæ
äžããŠãããããã®ãšãã«ã¯ãã®ãã©ã¡ãŒã¿ã®å€
åã¯èªããããŠããªãã€ãã ã€ãã«ããŒãžãšããçæ£è ã«ããããžãã¹ãã³
é žã®è¡äžã¢ã«ã«ãªãã¹ãã¢ã¿ãŒãŒæ¿åºŠã第ïŒè¡šã«
瀺ãã
åŸã«ããããªã³ãšã«ã«ã·ãŠã ã®ä»£è¬ãã©ã¡ãŒã¿ã
ãã³èæ§ãã©ã¡ãŒã¿ã«ã€ããŠèª¿ã¹ãã (A) ãªã³ããã³ã«ã«ã·ãŠã ã®ä»£è¬ãã©ã¡ãŒã¿ïŒè¡
äžã«ã«ã·ãŠã æ¿åºŠãè¡äžãªã³é žå¡©æ¿åºŠãè¡äžã¢
ã«ã«ãªãã¹ãã¢ã¿ãŒãŒæ¿åºŠãè¡æŒ¿äžPGE2ãè¡
挿äžå ç«åå¿æ§PTHãå°¿äžã«ã«ã·ãŠã æ¿åºŠã
å°¿äžãªã³é žå¡©æ¿åºŠãå°¿äžããããã·ãããªã³æ¿
床ãç°ç¶è 圢æAMPïŒcyclic nephrogenic
AMPïŒ (B) èæ§ãã©ã¡ãŒã¿ïŒãã¢ã¯ããŒã è¡çèšæž¬è©Š
éšãè¡äžã¿ã³ãã¯æ¿åºŠãè¡ç³æ¿åºŠãè¡äžããçŽ
æ¿åºŠãè¡äžã¯ã¬ã¢ãã³æ¿åºŠãè¡äžãã©ã³ã¹ã¢ã
ããŒãŒæ¿åºŠãå ç«ã°ãããªã³é ïŒè©ŠéšçµæïŒ ãããã®è¢«éšè ã«ãããŠãAHEDPæäžã«ãã€
ãŠèæ§ãã©ã¡ãŒã¿ã«ç®ç«ã€ãå€åãæ¹ããããã
ãšã¯ãªããããèæ§ã瀺ããããŸããšãã«å¯äœçš
ãèªããããªãã€ãããªã³ããã³ã«ã«ã·ãŠã ã®ä»£
è¬ãã©ã¡ãŒã¿ã«é¢ããéãããšãã«å€åã¯èªãã
ããªãã€ããããã«ã¯ãªã³é žå¡©è¡çã¯ãããã®æ
æã«ãããŠãèªããããªãã€ããã«ã«ã·ãŠã è¡ç
ããã³ã«ã«ã·ãŠã å°¿çã«é¢ããŠã¯ãæ°åã®è¢«éšè
ã«ãããŠéåžžã«çæéã§ã¯ãããèªãããããïŒ
æ¥ãããã®æäžéãïŒmgã10mgã20mgããã³40mg
ã®ãããã®ã°ããã«ãããŠãç²ç¶è ºæäœçšã«é¢ã
ããã©ã¡ãŒã¿ïŒè¡æŒ¿äžå ç«åå¿æ§PTHãç°ç¶è
圢æAMPïŒã®å€§ããªå€åã¯èªããããªãã€ãã å šäœçã«ã¯ããããã®ãã©ã¡ãŒã¿ã¯ãããã«å¢
å ããŠããããåé¡ãšãªãã¬ãã«ã«ãŸã§ã¯éããŠ
ããªãã€ãã AHEDPãïŒæ¥ãããïŒmgãŸãã¯10mgæäžãã
ã被éšè ã«ãããŠã¯ãç¡æ©ã«ã«ã·ãŠã ããã³ç¡æ©
ãªã³é žå¡©ã®å°¿ææ³éã¯ãšãã«æ¹åãããŠããªãã€
ãããAHEDPãïŒæ¥ããã20mgãŸãã¯40mgæäž
ããã被éšè ã«ãããŠã¯ããã®ïŒã€ã®ãã©ã¡ãŒã¿
ã«ããªãã®æ¹åãèªããããããã®å¹æã¯ãšãã«
ãªã³é žå¡©å°¿çã®ã°ããã«æçœã«èªããããã ãã¹ãŠè¢«éšè ãæ£ã€ãŠããé«ã¢ã«ã«ãªãã¹ãã¢
ã¿ãŒãŒè¡çããã³éªšèœçŽ°èçã¯ãïŒæ¥ãããã®æ
äžéãïŒã20mgã§ã¯æãããªæ¹åã¯èªããããã
ïŒæ¥ãããã®æåé40mgã®è¢«éšè ã«ãããŠã®ã¿æ
çœã§ãã€æ©æã®æ¹åãèªããããã ïŒããããã·ãããªã³ã®å°¿ææ³ïŒ 骚ã³ã©ãŒã²ã³ã®ç°åäœçšããã»ã¹ã®ææ°ã§ã
ããAHEDPæäžåã«è¢«éšè ã«ãããŠããªãé«ã
å€ã§ãã€ãããããã·ãããªã³ã®å°¿ææ³éã¯ãã
ã¹ãŠã®è¢«éšè ã«ãããŠããªãã®æžå°ãèªããã
ããããªãã¡ãããããã·ãããªã³ã®å°¿äžæ¿åºŠã¯
AHEDPæäžåã«ããã¹ãŠããªãæžå°ããæäžé
ãå€ãã»ã©ãã®å¹æãé«ããã®ã§ãã€ãã ããŒãžãšããçã®ïŒåã®è¢«éšè ã®ã°ããã
AHEDPæäžåã«ãããŠã¯éªšæº¶è§£çã®äœæ¶²ãã¢ã¯
ã¿ãŒã§ããè¡æŒ¿äžPGE2æ¿åºŠãããªãé«ãå€ã瀺
ããŠãããããããAHEDPãïŒæ¥ããã20ã40
mgæäžããããšã«ãã€ãŠãã®å€ã«ããªãã®ãã€æ©
æã®æžå°ãèªããããããªããã®ïŒåã®è¢«éšè ã®
ãã¡ïŒåã¯ãã®åã«ïŒæ¥ãããAHEDPã10mgæ
äžããŠãããããã®ãšãã«ã¯ãã®ãã©ã¡ãŒã¿ã®å€
åã¯èªããããŠããªãã€ãã ã€ãã«ããŒãžãšããçæ£è ã«ããããžãã¹ãã³
é žã®è¡äžã¢ã«ã«ãªãã¹ãã¢ã¿ãŒãŒæ¿åºŠã第ïŒè¡šã«
瀺ãã
ãè¡šã
第ïŒè¡šããæãããªããã«ãæ¬é¡çºæã®
AHEDPãæå¹æåãšãã骚代è¬ç°åžžæ²»çå€ãšã
åŒäŸïŒã®Cl2MDPãæå¹æåãšããå»è¬ãçµå£æ
äžã§ïŒæ¥ããã400mgã®æäžéã§ããŒãžãšããç
æ£è ã«æäžããã°ããïŒã«æéã®æäžæéåŸãæ£
è ã«ãããŠå¥åžžè ãããé«å€ã瀺ããŠããè¡äžã¢
ã«ã«ãªãã¹ãã¢ã¿ãŒãŒæ¿åºŠã®å€ãæžå°ãããã®å²
åã¯AHEDPã®æ¹ãCl2MDPãšæ¯èŒããŠãã倧ã
ããªã€ãŠããããŸã12ã«æéã®æäžåŸã§ã¯ã
Cl2MDPã®æ¹ãAHEDPãšæ¯èŒããŠãé«ãå€ã瀺
ããŠããããã®ããšããAHEDPã¯Cl2MDPãšæ¯
èŒããŠå¹æããã匷ãããã€ãã®äœçšãé·æéæ
ç¶ããã®ã«å¯ŸããŠãCl2MDPã§ã¯ããã®å¹æãæ
ç¶çã§ã¯ãªãããšãæããã§ããã ãã®ããã«æ¬é¡çºæã®AHEDPãæå¹æåãšã
ãå»è¬ã¯ãããŒãžãšããçæ£è ã«ãããŠã¢ã«ã«ãª
ãã¹ãã¢ã¿ãŒãŒæ¿åºŠãäžæããŠããã®ãæžå°ãã
ãç¹ã«ã€ããŠãåŒäŸïŒã«èšèŒãããCl2MDPãæ
å¹æåãšããå»è¬ã«èšåºé¢ã§ãã¡ããããåªããŠ
ãããã®ã§ããã ïŒèšåºåŠçè©Šéšã®çµè«ïŒ å šäœçã«è©äŸ¡ãããšãAHEDPæäžã«ãããã¹
ãŠã®è¢«éšè ã«ãããŠèæ§ãèªãããããã€å¥œãŸã
ããªãå¯äœçšãèªããããªãã€ãã°ãããè¡æ¶²åŠ
çæ§è³ªãèæ©èœããã³è æ©èœã«ããªãã®æ¹åãèª
ããããããŸãAHEDPæäžã«ããããããã·ã
ããªã³ã®å°¿ææ³éã®äœäžãæå¹ãã€éå¹çã«èªã
ããã骚ã®éåããã»ã¹ãæå¶ããå¹æãããã
ãšãå®èšŒããããéåžžã«èå³æ·±ãããšã«ã¯ã
AHEDPãïŒæ¥ãããïŒã20mgæäžããã°ããã
骚溶解ãé»æ¢ãã掻æ§ã¯èªãããããã®ã®ãè¡æŒ¿
äžã¢ã«ã«ãªãã¹ãã¢ã¿ãŒãŒæ¿åºŠã®æ¹åãèªããã
ãããããã€ãŠéªšèœçŽ°èã®æŽ»åã§ãã骚æ°çã®æ¹
åãèªããããªãã€ãããããã®ãã©ã¡ãŒã¿ã®æ¹
åã¯AHEDPãïŒæ¥ããã40mgæäžãã被éšè ã«
ãããŠã®ã¿èªããããã AHEDPæäžã®èæ§ãšå®å šæ§ã確èªããã®ã«ãš
ãã«éèŠãªäºå®ã¯ã被éšè ã®ãã¹ãŠã«äœæž©å¢å ã
è¡æ¶²ã®æ§è³ªå€åããŸã€ããèªããããªãã€ãããš
ã§ãããäžæ¹ããããã®ãã©ã¡ãŒã¿ã«é¢ããŠãæ¯
èŒäŸãšããŠçšããåæååç©ã®APDã¯ããªãã®
å€åãèªããããã åäžã®èšåºåŠçè©Šéšçµæã¯åè¿°ã®è¬çè©ŠéšããŒ
ã¿ãæ¯æããŠãããAHEDPã骚ã®éåãç°åžžã«
ã«ã·ãŠã æ²çãŸãã¯èåšã§ã®å€åã«ã«ã·ãŠã æ²ç
ãªã©ã®éªšä»£è¬ç°åžžã®æ²»çå€ãšããŠçšããã®ã«å å
ãªå€ã§ãã€ãã AHEDPã¯çµå£æäžãéçµå£æäžãŸãã¯å±ææ
äžã«å¥œé©ãªåœ¢æ ã«è£œå€ãããããã®å ·äœäŸãšããŠ
ã¯ãããšãã°ã€ãã«ç€ºããã®ããããããã (ã€) çµå£æäžïŒé å€ãã«ãã»ã«ãé¡ç²å€ãç³å€ã (ã) éçµå£æäžïŒçèå 泚å°ãéèå 泚å°ãé¢ç¯
å 泚å°ïŒïŒæº¶æ¶² (ã) å±ææäžïŒã¯ãªãŒã æ²»çã«äŸããã°ãããAHEDPã¯ã (a) çµå£æäžã§ã¯ïŒã50mgïŒKgäœéã (b) éçµå£æäžã§ã¯0.1ã20mgïŒKgäœéã (c) å±ææäžã§ã¯æå¹æåæ¿åºŠïŒã10ïŒ ã®ãã®ã
å¿ èŠéã ã®æäžéãšããã®ã奜ãŸããã åºåœ¢è£œå€ïŒé¡ç²å€ãã·ãŒã«ãããã«ãã»ã«ãé
å€ãç³å€ïŒã«çšãã賊圢å€ãšããŠã¯ãããšãã°ã·
ãŒã«ãããã«ãã»ã«ã®ã°ãããçšéå€ãç²å€ãå
é¢å€ïŒdisassociating agentïŒã最æ»å€ãå®å®å
å€ãé²è å€ãªã©ããããããå ·äœçã«ã¯ã€ãã®ã
ã®ããããããã ç³é¡ïŒã·ãšç³ãã°ã«ã³ãŒã¹ãã©ã¯ããŒã¹ãªã©ïŒã
ãã³ãã³ãŸãã¯ãã®èªå°äœïŒããŠã¢ãã³ã·ãã³ã
ã³ããžã€ã¬ã€ã¢ãã³ãã³ãªã©ïŒãã»ã«ããŒã¹ãŸã
ã¯ãã®èªå°äœïŒç²ç¶ã®åŸ®çŽ°ç²åç¶ã»ã«ããŒã¹ãã¡
ãã«ã»ã«ããŒã¹ããšãã«ã»ã«ããŒã¹ãã«ã«ããã·
ã¡ãã«ã»ã«ããŒã¹ãªã©ïŒããŽã ãŸãã¯ãŒã©ãã³
ïŒã¢ã©ãã¢ãŽã ããã©ã¬ã«ã³ããªã©ïŒãèèªé žãŸã
ã¯ãã®èªå°äœïŒã¹ãã¢ãªã³é žãã¹ãã¢ãªã³é žãã°
ãã·ãŠã ãã¹ãã¢ãªã³é žã«ã«ã·ãŠã ãã¹ãã¢ãªã³
é žãããªãŠã ãªã©ïŒãããªããããã·ååç©ïŒã
ã³ãããŒã«ããœã«ãããŒã«ãåºåœ¢ç¶ã®ããªãšãã¬
ã³ã°ãªã³ãŒã«ãªã©ïŒãè³éŠæãšã¹ãã«é¡ïŒïŒ°âã
ãããã·å®æ¯éŠé žã¡ãã«ãâããããã·å®æ¯éŠ
é žãããã«ãªã©ïŒãã¿ã«ã¯ãªã©ã 液ç¶è£œå€ã«çšãã賊圢å€ãšããŠã¯ãããšãã°ã
ãããã®ã°ããã液ç¶ããªããããã·ååç©ïŒãœ
ã«ãããŒã«F.U.ã®æº¶æ¶²ããããã¬ã³ã°ãªã³ãŒã«ã
ã°ãªã»ãªã³ãªã©ïŒãããããããåœç¶ã®ããšãªã
ãã粟補氎ãçšããããšãã§ãããäžè¬ã«æ°Žæº¶æ¶²
ã®ã°ãããé©åœã«äžåãããå®å®åãããè±èã
ãããã®ãçšããããããŸã泚å°çšæº¶æ¶²ã®ã°ãã
ãåæ§ã®è³Šåœ¢å€ãçšãããã çç®ãŸãã¯ç²èã«çŽæ¥å¡åžããã®ã«é©åœãªå±æ
æäžè£œå€ã«çšãã賊圢å€ãšããŠã¯ã溶åªïŒç¡è
æ°Žãããªããããã·ååç©ãªã©ïŒãå¢éå€ïŒã¢ã«
ã³ãŒã«ãèèªé žããããã®èªå°äœãªã©ïŒãä¹³åå€
ïŒã¹ãã¢ãªã³é žããªãšãã¬ã³ã°ãªã³ãŒã«ãšã¹ãã«ã
ã¬ã·ãã³ãããŠã€ãŒã³ãã¹ãã³ã¹ãªã©ïŒãå®å®å
å€ïŒïŒ°âããããã·å®æ¯éŠé žãšã¹ãã«é¡ã没é£å
é žãããã«ãšã¹ãã«ãªã©ïŒãç·©è¡å€ãªã©ãããã
ããã ã€ãã«è£œå€äŸããããã 補å€äŸïŒ ïŒäºéãã€ããåã®ã«ãã»ã«ïŒ ïŒæåïŒ ïŒïŒã«ãã»ã«äžã®å«æéïŒ AHEDP 400mg ç²ç¶ã©ã¯ããŒã¹ 45mg ã¿ã«ã¯ 20mg ãŒã©ãã³ ïŒmg ã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒmg 補å€äŸïŒ ïŒããããïŒ ïŒæåïŒ ïŒ10mläžã®å«æéïŒ AHEDP 20mg NaCl 40mg 0.1NâNaHCO3溶液 0.15ml âããããã·å®æ¯éŠé žã¡ãã« ïŒmg ç¡èæ°Ž ïŒml 補å€äŸïŒ ïŒé¡ç²å€ïŒ ïŒæåïŒ ïŒïŒå ãããã®å«æéïŒ AHEDP 200mg ã¿ã«ã¯ 10mg ã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒmg ã·ãªã«ã²ã« ïŒmg ããŠã¢ãã³ã·ãã³ãã³ ïŒmg 補å€äŸïŒ ïŒæå¹æåæ¿åºŠïŒïŒ ã®ã¯ãªãŒã ïŒ ïŒæåïŒ ïŒé åéïŒ AHEDP ïŒïœ ã»ã¿ããŒã« 18ïœ ãããã¬ã³ã°ãªã³ãŒã« 10ïœ PEGã¢ãã¹ãã¢ãªã³é žãšã¹ãã« ïŒïœ ã³ã¬ã¹ãããŒã«ã¹ãã¢ãªã³é žãšã¹ãã« ïŒïœ ãªããŒã«âãªããŒã«é ž 1.5ïœ é²è å€ããã³å®å®åå€ 0.5ïœ èžçæ°Ž 100ïœã
AHEDPãæå¹æåãšãã骚代è¬ç°åžžæ²»çå€ãšã
åŒäŸïŒã®Cl2MDPãæå¹æåãšããå»è¬ãçµå£æ
äžã§ïŒæ¥ããã400mgã®æäžéã§ããŒãžãšããç
æ£è ã«æäžããã°ããïŒã«æéã®æäžæéåŸãæ£
è ã«ãããŠå¥åžžè ãããé«å€ã瀺ããŠããè¡äžã¢
ã«ã«ãªãã¹ãã¢ã¿ãŒãŒæ¿åºŠã®å€ãæžå°ãããã®å²
åã¯AHEDPã®æ¹ãCl2MDPãšæ¯èŒããŠãã倧ã
ããªã€ãŠããããŸã12ã«æéã®æäžåŸã§ã¯ã
Cl2MDPã®æ¹ãAHEDPãšæ¯èŒããŠãé«ãå€ã瀺
ããŠããããã®ããšããAHEDPã¯Cl2MDPãšæ¯
èŒããŠå¹æããã匷ãããã€ãã®äœçšãé·æéæ
ç¶ããã®ã«å¯ŸããŠãCl2MDPã§ã¯ããã®å¹æãæ
ç¶çã§ã¯ãªãããšãæããã§ããã ãã®ããã«æ¬é¡çºæã®AHEDPãæå¹æåãšã
ãå»è¬ã¯ãããŒãžãšããçæ£è ã«ãããŠã¢ã«ã«ãª
ãã¹ãã¢ã¿ãŒãŒæ¿åºŠãäžæããŠããã®ãæžå°ãã
ãç¹ã«ã€ããŠãåŒäŸïŒã«èšèŒãããCl2MDPãæ
å¹æåãšããå»è¬ã«èšåºé¢ã§ãã¡ããããåªããŠ
ãããã®ã§ããã ïŒèšåºåŠçè©Šéšã®çµè«ïŒ å šäœçã«è©äŸ¡ãããšãAHEDPæäžã«ãããã¹
ãŠã®è¢«éšè ã«ãããŠèæ§ãèªãããããã€å¥œãŸã
ããªãå¯äœçšãèªããããªãã€ãã°ãããè¡æ¶²åŠ
çæ§è³ªãèæ©èœããã³è æ©èœã«ããªãã®æ¹åãèª
ããããããŸãAHEDPæäžã«ããããããã·ã
ããªã³ã®å°¿ææ³éã®äœäžãæå¹ãã€éå¹çã«èªã
ããã骚ã®éåããã»ã¹ãæå¶ããå¹æãããã
ãšãå®èšŒããããéåžžã«èå³æ·±ãããšã«ã¯ã
AHEDPãïŒæ¥ãããïŒã20mgæäžããã°ããã
骚溶解ãé»æ¢ãã掻æ§ã¯èªãããããã®ã®ãè¡æŒ¿
äžã¢ã«ã«ãªãã¹ãã¢ã¿ãŒãŒæ¿åºŠã®æ¹åãèªããã
ãããããã€ãŠéªšèœçŽ°èã®æŽ»åã§ãã骚æ°çã®æ¹
åãèªããããªãã€ãããããã®ãã©ã¡ãŒã¿ã®æ¹
åã¯AHEDPãïŒæ¥ããã40mgæäžãã被éšè ã«
ãããŠã®ã¿èªããããã AHEDPæäžã®èæ§ãšå®å šæ§ã確èªããã®ã«ãš
ãã«éèŠãªäºå®ã¯ã被éšè ã®ãã¹ãŠã«äœæž©å¢å ã
è¡æ¶²ã®æ§è³ªå€åããŸã€ããèªããããªãã€ãããš
ã§ãããäžæ¹ããããã®ãã©ã¡ãŒã¿ã«é¢ããŠãæ¯
èŒäŸãšããŠçšããåæååç©ã®APDã¯ããªãã®
å€åãèªããããã åäžã®èšåºåŠçè©Šéšçµæã¯åè¿°ã®è¬çè©ŠéšããŒ
ã¿ãæ¯æããŠãããAHEDPã骚ã®éåãç°åžžã«
ã«ã·ãŠã æ²çãŸãã¯èåšã§ã®å€åã«ã«ã·ãŠã æ²ç
ãªã©ã®éªšä»£è¬ç°åžžã®æ²»çå€ãšããŠçšããã®ã«å å
ãªå€ã§ãã€ãã AHEDPã¯çµå£æäžãéçµå£æäžãŸãã¯å±ææ
äžã«å¥œé©ãªåœ¢æ ã«è£œå€ãããããã®å ·äœäŸãšããŠ
ã¯ãããšãã°ã€ãã«ç€ºããã®ããããããã (ã€) çµå£æäžïŒé å€ãã«ãã»ã«ãé¡ç²å€ãç³å€ã (ã) éçµå£æäžïŒçèå 泚å°ãéèå 泚å°ãé¢ç¯
å 泚å°ïŒïŒæº¶æ¶² (ã) å±ææäžïŒã¯ãªãŒã æ²»çã«äŸããã°ãããAHEDPã¯ã (a) çµå£æäžã§ã¯ïŒã50mgïŒKgäœéã (b) éçµå£æäžã§ã¯0.1ã20mgïŒKgäœéã (c) å±ææäžã§ã¯æå¹æåæ¿åºŠïŒã10ïŒ ã®ãã®ã
å¿ èŠéã ã®æäžéãšããã®ã奜ãŸããã åºåœ¢è£œå€ïŒé¡ç²å€ãã·ãŒã«ãããã«ãã»ã«ãé
å€ãç³å€ïŒã«çšãã賊圢å€ãšããŠã¯ãããšãã°ã·
ãŒã«ãããã«ãã»ã«ã®ã°ãããçšéå€ãç²å€ãå
é¢å€ïŒdisassociating agentïŒã最æ»å€ãå®å®å
å€ãé²è å€ãªã©ããããããå ·äœçã«ã¯ã€ãã®ã
ã®ããããããã ç³é¡ïŒã·ãšç³ãã°ã«ã³ãŒã¹ãã©ã¯ããŒã¹ãªã©ïŒã
ãã³ãã³ãŸãã¯ãã®èªå°äœïŒããŠã¢ãã³ã·ãã³ã
ã³ããžã€ã¬ã€ã¢ãã³ãã³ãªã©ïŒãã»ã«ããŒã¹ãŸã
ã¯ãã®èªå°äœïŒç²ç¶ã®åŸ®çŽ°ç²åç¶ã»ã«ããŒã¹ãã¡
ãã«ã»ã«ããŒã¹ããšãã«ã»ã«ããŒã¹ãã«ã«ããã·
ã¡ãã«ã»ã«ããŒã¹ãªã©ïŒããŽã ãŸãã¯ãŒã©ãã³
ïŒã¢ã©ãã¢ãŽã ããã©ã¬ã«ã³ããªã©ïŒãèèªé žãŸã
ã¯ãã®èªå°äœïŒã¹ãã¢ãªã³é žãã¹ãã¢ãªã³é žãã°
ãã·ãŠã ãã¹ãã¢ãªã³é žã«ã«ã·ãŠã ãã¹ãã¢ãªã³
é žãããªãŠã ãªã©ïŒãããªããããã·ååç©ïŒã
ã³ãããŒã«ããœã«ãããŒã«ãåºåœ¢ç¶ã®ããªãšãã¬
ã³ã°ãªã³ãŒã«ãªã©ïŒãè³éŠæãšã¹ãã«é¡ïŒïŒ°âã
ãããã·å®æ¯éŠé žã¡ãã«ãâããããã·å®æ¯éŠ
é žãããã«ãªã©ïŒãã¿ã«ã¯ãªã©ã 液ç¶è£œå€ã«çšãã賊圢å€ãšããŠã¯ãããšãã°ã
ãããã®ã°ããã液ç¶ããªããããã·ååç©ïŒãœ
ã«ãããŒã«F.U.ã®æº¶æ¶²ããããã¬ã³ã°ãªã³ãŒã«ã
ã°ãªã»ãªã³ãªã©ïŒãããããããåœç¶ã®ããšãªã
ãã粟補氎ãçšããããšãã§ãããäžè¬ã«æ°Žæº¶æ¶²
ã®ã°ãããé©åœã«äžåãããå®å®åãããè±èã
ãããã®ãçšããããããŸã泚å°çšæº¶æ¶²ã®ã°ãã
ãåæ§ã®è³Šåœ¢å€ãçšãããã çç®ãŸãã¯ç²èã«çŽæ¥å¡åžããã®ã«é©åœãªå±æ
æäžè£œå€ã«çšãã賊圢å€ãšããŠã¯ã溶åªïŒç¡è
æ°Žãããªããããã·ååç©ãªã©ïŒãå¢éå€ïŒã¢ã«
ã³ãŒã«ãèèªé žããããã®èªå°äœãªã©ïŒãä¹³åå€
ïŒã¹ãã¢ãªã³é žããªãšãã¬ã³ã°ãªã³ãŒã«ãšã¹ãã«ã
ã¬ã·ãã³ãããŠã€ãŒã³ãã¹ãã³ã¹ãªã©ïŒãå®å®å
å€ïŒïŒ°âããããã·å®æ¯éŠé žãšã¹ãã«é¡ã没é£å
é žãããã«ãšã¹ãã«ãªã©ïŒãç·©è¡å€ãªã©ãããã
ããã ã€ãã«è£œå€äŸããããã 補å€äŸïŒ ïŒäºéãã€ããåã®ã«ãã»ã«ïŒ ïŒæåïŒ ïŒïŒã«ãã»ã«äžã®å«æéïŒ AHEDP 400mg ç²ç¶ã©ã¯ããŒã¹ 45mg ã¿ã«ã¯ 20mg ãŒã©ãã³ ïŒmg ã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒmg 補å€äŸïŒ ïŒããããïŒ ïŒæåïŒ ïŒ10mläžã®å«æéïŒ AHEDP 20mg NaCl 40mg 0.1NâNaHCO3溶液 0.15ml âããããã·å®æ¯éŠé žã¡ãã« ïŒmg ç¡èæ°Ž ïŒml 補å€äŸïŒ ïŒé¡ç²å€ïŒ ïŒæåïŒ ïŒïŒå ãããã®å«æéïŒ AHEDP 200mg ã¿ã«ã¯ 10mg ã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒmg ã·ãªã«ã²ã« ïŒmg ããŠã¢ãã³ã·ãã³ãã³ ïŒmg 補å€äŸïŒ ïŒæå¹æåæ¿åºŠïŒïŒ ã®ã¯ãªãŒã ïŒ ïŒæåïŒ ïŒé åéïŒ AHEDP ïŒïœ ã»ã¿ããŒã« 18ïœ ãããã¬ã³ã°ãªã³ãŒã« 10ïœ PEGã¢ãã¹ãã¢ãªã³é žãšã¹ãã« ïŒïœ ã³ã¬ã¹ãããŒã«ã¹ãã¢ãªã³é žãšã¹ãã« ïŒïœ ãªããŒã«âãªããŒã«é ž 1.5ïœ é²è å€ããã³å®å®åå€ 0.5ïœ èžçæ°Ž 100ïœã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ åŒïŒïŒïŒ ã§è¡šããããïŒâã¢ããâïŒâããããã·ãããµ
ã³âïŒïŒïŒâãžãã¹ãã³é žããã®é žä»å å¡©ããã®
ãšã¹ãã«åç©ãŸãã¯ãããšé ãšã®ãã¬ãŒãé¯åå
ç©ãæå¹æåãšãã骚代è¬ç°åžžæ²»çå€ã ïŒ å°ãªããšãïŒçš®ã®ãã€ãªã€ãŒãçšããŠã€ãã
ããŠããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ²»çå€ã ïŒ çµå£æäžã«å¥œé©ãªåœ¢æ ã«è£œå€ãããŠããç¹èš±
è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ²»çå€ã ïŒ éçµå£æäžã«å¥œé©ãªåœ¢æ ã«è£œå€ãããŠããç¹
èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ²»çå€ã ïŒ å±ææäžã«å¥œé©ãªåœ¢æ ã«è£œå€ãããŠããç¹èš±
è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ²»çå€ã
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT19673/81A IT1194748B (it) | 1981-02-12 | 1981-02-12 | Composizioni farmaceutiche per il trattamento di osteopatie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57167915A JPS57167915A (en) | 1982-10-16 |
| JPS637526B2 true JPS637526B2 (ja) | 1988-02-17 |
Family
ID=11160281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57020614A Granted JPS57167915A (en) | 1981-02-12 | 1982-02-10 | Osteopathic remedy |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4578376A (ja) |
| JP (1) | JPS57167915A (ja) |
| BE (1) | BE891891A (ja) |
| CA (1) | CA1174602A (ja) |
| DE (1) | DE3201865C2 (ja) |
| FR (1) | FR2499408B1 (ja) |
| GB (1) | GB2096889B (ja) |
| IT (1) | IT1194748B (ja) |
| LU (1) | LU83931A1 (ja) |
| NL (1) | NL8200298A (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04503650A (ja) * | 1989-02-27 | 1992-07-02 | ãŠãããã¯ãã³ãŒãã¬ã€ã·ã§ã³ | 容åšçšã®ïœâã¿ãã€ã³ãã·ãŒã«åã³ãã®è£ çæ¹æ³ |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1201087B (it) * | 1982-04-15 | 1989-01-27 | Gentili Ist Spa | Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche |
| DE3225469A1 (de) * | 1982-07-05 | 1984-01-05 | Schering AG, 1000 Berlin und 4709 Bergkamen | Diphosphonsaeure-derivate und diese enthaltende pharmazeutische praeparate |
| IT1195993B (it) * | 1984-01-12 | 1988-11-03 | Gentili Ist Spa | Forme farmaceutiche a base di difosfonati |
| DE3434667A1 (de) * | 1984-09-21 | 1986-04-03 | Henkel KGaA, 4000 DÃŒsseldorf | 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung |
| IT1187828B (it) * | 1985-05-24 | 1987-12-23 | Gentili Ist Spa | Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi |
| GB8618259D0 (en) * | 1986-07-25 | 1986-09-03 | Leo Pharm Prod Ltd | Pharmaceutical compositions |
| US4889725A (en) * | 1987-04-17 | 1989-12-26 | Veltman Preston Leonard | Means to promote the neutralization reaction between particulate calcium carbonate and ionized phosphate |
| US5356887A (en) * | 1990-01-31 | 1994-10-18 | Merck & Co., Inc. | Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids |
| US5019651A (en) * | 1990-06-20 | 1991-05-28 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof |
| US5341305A (en) * | 1991-05-02 | 1994-08-23 | Gerber Garment Technology, Inc. | A computerized pattern development system capable of direct designer input |
| IT1247034B (it) * | 1991-06-26 | 1994-12-12 | Gentili Ist Spa | Acidi dimetilamino-idrossi alchil difosfonici e loro sali, loro procedimento produttivo e composizioni farmaceutiche che li comprendono |
| FR2703590B1 (fr) * | 1993-04-05 | 1995-06-30 | Sanofi Elf | Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse . |
| US20010007863A1 (en) * | 1998-06-18 | 2001-07-12 | Merck & Co., Inc. | Wet granulation formulation for bisphosphonic acids |
| MXPA06003063A (es) * | 2003-09-19 | 2006-05-31 | Pfizer Prod Inc | Composiciones farmaceuticas y metodos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina- d y un bisfosfonato. |
| US9211257B2 (en) * | 2012-05-14 | 2015-12-15 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
| US9079630B2 (en) | 2013-08-15 | 2015-07-14 | Harley-Davidson Motor Company Group, LLC | Steering stem assembly for a motorcycle |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4134969A (en) * | 1974-02-04 | 1979-01-16 | Henkel Kommanditgesellschaft Auf Aktien (Henkel Kgaa) | Method of treatment of calcium disorders using aminoalkane-diphosphonic acids |
| DE2405254C2 (de) * | 1974-02-04 | 1982-05-27 | Henkel KGaA, 4000 DÃŒsseldorf | Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsÀure oder ihrer wasserlöslichen Salze bei der BeeinfluÃung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper |
| US4230700A (en) * | 1977-12-07 | 1980-10-28 | The Procter & Gamble Company | Methods for inhibiting mobilization of calcium phosphate in animal tissue |
| DE3016289A1 (de) * | 1980-04-28 | 1981-10-29 | Henkel KGaA, 4000 DÃŒsseldorf | Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren |
| FR2489334A1 (fr) * | 1980-09-04 | 1982-03-05 | Vysoka Skola Chem Tech | Acide 6-amino-1-hydroxyhexilidene-diphosphonique, ses sels, et procede pour l'obtention de ces produits |
| BE885139A (fr) * | 1981-03-09 | 1981-03-09 | Vs Chemicko Technologicka Prah | Acide 6-amino-1-hydroxyhexylidene-disphosphonique, sels de cet acide et procede de fabrication de ces produits |
-
1981
- 1981-02-12 IT IT19673/81A patent/IT1194748B/it active
-
1982
- 1982-01-22 DE DE3201865A patent/DE3201865C2/de not_active Expired
- 1982-01-25 CA CA000394816A patent/CA1174602A/en not_active Expired
- 1982-01-26 BE BE2/59556A patent/BE891891A/fr not_active IP Right Cessation
- 1982-01-27 NL NL8200298A patent/NL8200298A/nl active Search and Examination
- 1982-02-02 GB GB8202894A patent/GB2096889B/en not_active Expired
- 1982-02-10 LU LU83931A patent/LU83931A1/fr unknown
- 1982-02-10 FR FR8202192A patent/FR2499408B1/fr not_active Expired
- 1982-02-10 JP JP57020614A patent/JPS57167915A/ja active Granted
-
1984
- 1984-12-03 US US06/677,177 patent/US4578376A/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04503650A (ja) * | 1989-02-27 | 1992-07-02 | ãŠãããã¯ãã³ãŒãã¬ã€ã·ã§ã³ | 容åšçšã®ïœâã¿ãã€ã³ãã·ãŒã«åã³ãã®è£ çæ¹æ³ |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS57167915A (en) | 1982-10-16 |
| BE891891A (fr) | 1982-05-17 |
| NL8200298A (nl) | 1982-09-01 |
| LU83931A1 (fr) | 1982-12-13 |
| CA1174602A (en) | 1984-09-18 |
| GB2096889B (en) | 1985-05-09 |
| US4578376A (en) | 1986-03-25 |
| FR2499408A1 (fr) | 1982-08-13 |
| IT8119673A0 (it) | 1981-02-12 |
| DE3201865C2 (de) | 1986-12-11 |
| FR2499408B1 (fr) | 1985-10-18 |
| DE3201865A1 (de) | 1982-08-19 |
| IT1194748B (it) | 1988-09-28 |
| GB2096889A (en) | 1982-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS637526B2 (ja) | ||
| NL192562C (nl) | Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat. | |
| US4066678A (en) | 3-trihydroxygermyl propionic acid and its salts and a process for the production thereof | |
| US6489312B1 (en) | Pharmaceutical formulations comprising aminoalkyl phosphorothioates | |
| EP0674904B1 (en) | Use of phosphoric acid diester compounds for suppressing hepatic metastases of tumors | |
| CA2409930A1 (en) | Use of zoledronate for the manufacture of a medicament for the treatment of bone metabolism diseases | |
| JPH04211015A (ja) | ãã¹ãã¹ãã³é žã®äžæº¶æ§å¡©ãå«æããè¬å€çµæç© | |
| JPH04505760A (ja) | ïœïœã®å¯äœçšããã³æ¯æ§ããã®ä¿è·æ¹æ³ | |
| KR100363692B1 (ko) | ì¹ë£ì ì©ëìíŒëŠ¬ëë¹ì€ìžì°ìŒ | |
| US5885973A (en) | Bone mass anabolic composition comprising olpadronate | |
| US5407924A (en) | Method of treating pain using inositol triphosphate | |
| JPH0415235B2 (ja) | ||
| EP0800397B1 (en) | Bone mass anabolic composition comprising olpadronate | |
| CN101781330B (zh) | äžæ³é ç£·é žé ¯æ°šåºé žå€çåå ¶å¶å€æ¹æ³ååºçš | |
| EP0623623B1 (en) | 2-aminoethanesulfonic acid/zinc complex | |
| US4402982A (en) | Antihypertension treatment and composition therefor | |
| NL7902233A (nl) | Werkwijze voor het bereiden van een geneesmiddel voor het behandelen van niet-neoplastische obstructieve icterus. | |
| KR20200085441A (ko) | ìŽë°ëë¡ë€ìŽížì ì ê·í ê²°ì í ë° ìŽì ì ì¡°ë°©ë² | |
| WO1994009790A1 (en) | The use of inositoltrisphosphate for the preparation of medicaments | |
| MXPA96006180A (en) | Piridilbisphosphonates to be used as a therapist agent |